Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Assets (2022 - 2025)

Taysha Gene Therapies' Current Assets history spans 4 years, with the latest figure at $300.0 million for Q3 2025.

  • For Q3 2025, Current Assets rose 85.66% year-over-year to $300.0 million; the TTM value through Sep 2025 reached $300.0 million, up 85.66%, while the annual FY2024 figure was $142.1 million, 5.16% down from the prior year.
  • Current Assets for Q3 2025 was $300.0 million at Taysha Gene Therapies, down from $316.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $316.3 million in Q2 2025 and bottomed at $43.0 million in Q3 2022.
  • The 4-year median for Current Assets is $130.6 million (2024), against an average of $141.4 million.
  • The largest YoY upside for Current Assets was 299.53% in 2023 against a maximum downside of 32.31% in 2023.
  • A 4-year view of Current Assets shows it stood at $96.4 million in 2022, then soared by 55.44% to $149.9 million in 2023, then fell by 5.16% to $142.1 million in 2024, then skyrocketed by 111.04% to $300.0 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Current Assets are $300.0 million (Q3 2025), $316.3 million (Q2 2025), and $120.7 million (Q1 2025).